CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Influence of Heart Rate on FFR Measurements: An Experimental and Clinical Validation Study Definition and Management of Segmental Pulmonary Hypertension Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club Pulmonary hypertension related to congenital heart disease: a call for action Unprotected Left Main Disease: Indications and Optimal Strategies for Percutaneous Intervention Parallel Murine and Human Plaque Proteomics Reveals Pathways of Plaque Rupture Evolving understanding of the heterogeneous natural history of individual coronary artery plaques and the role of local endothelial shear stress Transthoracic echocardiography for the evaluation of children and adolescents with suspected or confirmed pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and D6PK Pulmonary Hypertension Caused by a Coconut Left Atrium Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk

Review Article2017 Oct 24;70(17):2186-2200.

JOURNAL:J Am Coll Cardiol. Article Link

Biological Phenotypes of Heart Failure With Preserved Ejection Fraction

Lewis GA, Schelbert EB, Miller CA et al. Keywords: diastolic dysfunction; ejection fraction; heart failure; heart failure with preserved ejection fraction; myocardial fibrosis; titin

ABSTRACT

Heart failure with preserved ejection fraction (HFpEF) involves multiple pathophysiological mechanisms, which result in the heterogeneous phenotypes that are evident clinically, and which have potentially confounded previous HFpEF trials. A greater understanding of the in vivo human processes involved, and in particular, which are the causes and which are the downstream effects, may allow the syndrome of HFpEF to be distilled into distinct diagnoses based on the underlying biology. From this, specific interventions can follow, targeting individuals identified on the basis of their biological phenotype. This review describes the biological phenotypes of HFpEF and therapeutic interventions aimed at targeting these phenotypes.